Gufic Biosciences Limited — PPTs, 13-08-2025: Investor Presentation

Here's a summary of Gufic Biosciences Limited's Q1 FY26 updates:

**1. Financial Highlights:**

Q1 FY26 revenue grew to 226.9 Cr YoY, but Profit After Tax declined to 12.1 Cr (5.33% margin). This margin pressure is linked to the strategic ramp-up of the new Indore injectable facility.

**2. Strategic Initiatives & Growth Drivers:**

The new Indore injectable facility, operational since Oct 2024, is a key driver, aiming for 30% utilization and EBITDA breakeven in FY26, with margin accretion from FY27.

**3. Business Developments:**

Gufic launched India's first immune therapy for recurrent implantation failure and new Critical Care products. NeuroCare saw strong growth (107% value, 133% units YoY), boosting market share, while international business secured UK NHS tenders.

**4. Market Position & Competitive Advantage:**

Gufic is a leading lyophilized injectables manufacturer, leveraging its advanced Indore facility for complex products. Its competitive edge is in pioneering first-in-India therapies and unique launches, solidifying niche leadership.

**5. Investor Implications:**

Despite Q1 FY26 margin compression, the Indore facility's ramp-up signals positive long-term growth potential. The company's focus on complex, differentiated products and market expansion suggests a robust outlook.